Does IMAX Corporation have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores IMAX Corporation (IMAX) 61.1 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 80, pricing power 66, returns on capital 35, balance-sheet safety 51, capital allocation 74.

Is IMAX trading below the conservative owner-earnings estimate?

The value if growth stopped today — a zero-growth baseline — is $16.25 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $51.64, that is 218% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.

How has IMAX's Moat Score changed over time?

The record logs 18 readings since Jul 17, 2026; the latest reads 61.1 out of 100 (narrow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

IMAX Corporation

IMAX · Healthcare · $2.8B mkt cap · FY2025 filings · as of Sep 7, 2026 · Narrow moat ·

On the watchlist

Narrow moat

The five investor questions

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $255M to $410M, increasing; diluted EPS -0.38 to 0.63, increasing.

Median gross margin 53.9% over 10y, variable.

Median ROIC 9.8%, above the 12% hurdle in 40% of years.

Net debt/EBITDA n/ax, interest coverage 11x.

Owner earnings changed +4.5%/yr over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today

218% above value if growth stopped today

: $78.9M
: $16.25
: $16.25
: $51.64
: 218% above value if growth stopped today

What today’s price assumes: owner earnings growing ~26%/yr over 5 years. The zero-growth estimate assumes owner earnings stay flat (0% growth).

How to read this

We solve for the constant annual change in owner earnings that would make the five-year zero-growth estimate equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 235% above the zero-growth estimate across 49 of the current top 50 companies by Moat Score with both values.

Score records captured Sep 7, 2026.

Exactly which 50 companies?

FTNT, META, MEDP, IBEX, MSFT, GOOG, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, RMD, GRMN, PCTY, EAT, UI, SSD, MNST, DOCS, LRCX, MCO, CPRT, NTAP, NVDA, CORT, SFM, MPTI, ULTA, SN, ROL, CTAS, PAYC, IRMD, INTU, DECK, MORN, JKHY, TPR, LGCY, DAL, GWW, ISRG, MPWR, LOPE

Missing a usable price or zero-growth estimate: ANF.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

18 years of fundamentals

The business, in plain English

IMAX Corporation booked $410M of revenue in FY2025 in the Healthcare sector and kept 60.0% of it as gross profit — a high-margin business by that measure. After every other cost, 8.5% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $171M (FY2009) to $410M (FY2025) — about 5.6% a year compounded over 16 years.

It earned 32.4% on invested capital in the latest filed year, FY2025. Across the full 17-year measurable filed record, median ROIC was 15.7%. Over the v3 recent window (10 measurable filed years), median ROIC was 9.8%. The Returns on Capital filter above scores it 35/100.

IMAX's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.

Put together: Business Trend is the strongest of the five filters (80/100) and Returns on Capital the weakest (35/100), which is how IMAX lands at 61/100 — a Narrow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

Sales, as filed$410M FY2025

Revenue kept after cost of goods60.0% FY2025

Standard ROIC or separately labeled Operating ROICStandard ROIC 0.0% FY2021

Exact FY and FY-1 financing invested-capital inputs are required.

Cash an owner could take out$89.2M FY2025

The explained ROIC gaps have filed inputs but no meaningful positive invested-capital denominator. Other gaps mean the item is not in the filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How IMAX Corporation makes its money

Start with a dollar of revenue and follow what the filing says remains.

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed line	Value	% of revenue	Source
	$410M	100%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
Cost of revenue	$164M	40%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
	$246M	60%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
	$84.2M	21%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
Income before tax	$63.3M	15%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
Income tax	$17.8M	4%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
	$34.9M	9%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026

Source:

10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026

· event Dec 31, 2025 · retrieved Sep 7, 2026 · annual-row source set

Embed this chart

Flagship explainer

What IMAX Corporation owns — and owes

IMAX Corporation's filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed line	Value	% of assets	Source
Total assets	$894M	100%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
Cash and equivalents	$151M	17%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
Stockholders’ equity	$338M	38%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026

Source:

10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026

· event Dec 31, 2025 · retrieved Sep 7, 2026 · annual-row source set

Flagship explainer

What drives IMAX Corporation’s return on equity?

ROE is five filed business factors multiplied together.

DuPont source inputs
Input	Value	Fiscal year	Source
	$34.9M	FY2025	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
Income before tax	$63.3M	FY2025	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
Operating income	$84.2M	FY2025	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
	$410M	FY2025	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
Ending assets	$894M	FY2025	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
Beginning assets	$830M	FY2024	10-K · FY 2024Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
	$338M	FY2025	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
	$299M	FY2024	10-K · FY 2024Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026

Source:

10-K · filed Feb 25, 2026Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026

· event Dec 31, 2025 · retrieved Sep 7, 2026 · annual-row source set

Embed this chart

Flagship explainer

Where IMAX Corporation's cash went

IMAX Corporation’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed line	Value	% of cash from operations	Source
Cash from operations	$127M	100%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026
Depreciation and amortization	$62.4M	49%	10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026

Source:

10-K · FY 2025Filing detailsAccession 0001628280-26-011770 · filed Feb 25, 2026

· event Dec 31, 2025 · retrieved Sep 7, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding IMAX Corporation

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited0 not holding0/19 resolved19 not retrieved

Named manager positions and quarter-over-quarter changes
Manager	Reported position	Quarter-over-quarter	Filing accession
Abrams Capital	Not retrieved	Comparison not retrieved	Filing not retrieved
Akre Capital	Not retrieved	Comparison not retrieved	Filing not retrieved
Baupost Group	Not retrieved	Comparison not retrieved	Filing not retrieved
Berkshire Hathaway	Not retrieved	Comparison not retrieved	Filing not retrieved
Brave Warrior Advisors	Not retrieved	Comparison not retrieved	Filing not retrieved
Dodge & Cox	Not retrieved	Comparison not retrieved	Filing not retrieved
First Eagle	Not retrieved	Comparison not retrieved	Filing not retrieved
Fundsmith	Not retrieved	Comparison not retrieved	Filing not retrieved
Gardner Russo & Quinn	Not retrieved	Comparison not retrieved	Filing not retrieved
Gates Foundation Trust	Not retrieved	Comparison not retrieved	Filing not retrieved
Mairs & Power	Not retrieved	Comparison not retrieved	Filing not retrieved
Markel / Markel-Gayner	Not retrieved	Comparison not retrieved	Filing not retrieved
Oakmark / Harris Associates	Not retrieved	Comparison not retrieved	Filing not retrieved
Pershing Square	Not retrieved	Comparison not retrieved	Filing not retrieved
Polen Capital	Not retrieved	Comparison not retrieved	Filing not retrieved
Sequoia / Ruane Cunniff	Not retrieved	Comparison not retrieved	Filing not retrieved
Southeastern Asset Management	Not retrieved	Comparison not retrieved	Filing not retrieved
Tweedy, Browne	Not retrieved	Comparison not retrieved	Filing not retrieved
Yacktman Asset Management	Not retrieved	Comparison not retrieved	Filing not retrieved

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: Filing source not retrieved · event Jun 30, 2026 · retrieved Sep 7, 2026

Flagship explainer

What IMAX Corporation insiders reported

We could not retrieve insider activity for this rendering; no zero-activity claim is shown.

Unavailable: Form 4 activity could not be retrieved for this rendering.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale61.1 / 100

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for IMAX.

Track record

How IMAX Corporation’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored IMAX on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the 2 years IMAX rated Wide-moat (2013 and 2016), the median forward total return that followed — measured only after each year’s filings were public — was:

1 year −12% vs the S&P 500’s 16% (price basis) · median over 2 years
3 years −13% vs the S&P 500’s 34% (price basis) · median over 2 years
5 years −38% vs the S&P 500’s 75% (price basis) · median over 2 years

These are medians computed from the data, not a claim about any one year. The company figures are total returns (dividends reinvested); the S&P 500 is the price-only ^GSPC index, which excludes dividends and so understates the index — the gap flatters the company. A quality rating is not a return forecast, and past returns don’t predict future ones. Educational only, not investment advice.

Healthcare context

#102 of 708 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#100CDRE Cadre Holdings, Inc.61.4 out of 100, Narrow moatNarrow moat
#101BIOE BIO ESSENCE CORP.61.2 out of 100, Narrow moatNarrow moat
#103CBLL CeriBell, Inc.61.1 out of 100, Narrow moatNarrow moat
#104ACAD ACADIA PHARMACEUTICALS INC.61.0 out of 100, Narrow moatNarrow moat

Compare IMAX with its nearest peers →All Healthcare companies on the Index →

Common questions about IMAX

Does IMAX Corporation have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores IMAX Corporation (IMAX) 61.1 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 80, pricing power 66, returns on capital 35, balance-sheet safety 51, capital allocation 74.
Is IMAX trading below the conservative owner-earnings estimate?: The value if growth stopped today — a zero-growth baseline — is $16.25 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $51.64, that is 218% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
How has IMAX's Moat Score changed over time?: The record logs 18 readings since Jul 17, 2026; the latest reads 61.1 out of 100 (narrow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell IMAX. See the disclaimer.